Corcept Initiates Trial of Relacorilant Plus Nab-Paclitaxel and Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...
Research Analysts Set Expectations for CORT Q1 Earnings
Equities researchers at Zacks Research lifted their Q1 2026 earnings per share (EPS) estimates for shares of Corcept ...
CURE6h
BELLA Clinical Trial Initiated in Platinum-Resistant Ovarian Cancer
The BELLA phase 2 clinical trial of relacorilant plus nab-paclitaxel and Avastin among patients with platinum-resistant ...
Le Lézard9h
Sail Biomedicines Appoints Laura Sepp-Lorenzino, Ph.D., to Its Board of Directors
Sail Biomedicines, Inc. ("Sail"), a Flagship Pioneering company and leader in RNA-based programmable medicines, today announced that Laura Sepp-Lorenzino, Ph.D., has joined its Board of Directors. Dr.
Le Lézard9h
ICU Medical Introduces Its New Category of Infusion Devices With FDA Clearances of Plum Solotm and Plum Duotm Precision IV Pumps
ICU Medical Inc. , a worldwide leader in the development, manufacture and sale of innovative medical devices, has announced ...